<div id="readability-page-1"><div>CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. The updated release reads: DYNAVAX INVESTOR ALERT: KAHN SWICK &amp; FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Dynavax will receive $15.50 in cash for each share of Dynavax that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-dvax/ to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk4MTk0MTNyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk4MTk0MTNyMg"/> Kahn Swick &amp; Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20251229819413/en/</div></div>

德纳维制药

Kahn Swick & Foti, LLC 正在调查 Dynavax Technologies Corporation (DVAX) 拟议出售给赛诺菲的事宜，股东将获得每股 15.50 美元。该公司旨在评估这一价格的合理性以及导致此次出售的过程，质疑是否低估了该公司的价值。感兴趣的各方可以联系 KSF 以获取有关其在此事中的法律权利的更多信息

CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

更正并替换德纳维制药投资者警报：Kahn Swick & Foti, LLC 正在调查德纳维制药公司拟议出售中的价格和流程是否充分 - DVAX